Kansas City, MO,
10
October
2018
|
09:06 PM
Europe/Amsterdam

Goldman Receives RO1 Grant from NIH

Jennifer Goldman, MD, Director of the Antimicrobial Stewardship Program and the Drug Safety Service in the Division of Infectious Diseases and Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation at Children's Mercy Kansas City, has been awarded a five-year, $1,364,567 R01 grant from the National Institute of General Medical Sciences.

Dr. Goldman’s “Trimethoprim: an overlooked contributor of trimethoprim-sulfamethoxazole idiosyncratic adverse drug reactions” study will define mechanisms associated with trimethoprim induced adverse reactions, the drug component which has been overlooked and understudied as a likely contributor to idiosyncratic adverse drug reactions. This information is critical for the future development of tools that can predict those at greatest risk and thereby enhance safe prescribing of this critical antibiotic.

Boilerplate

Children’s Mercy Kansas City is ranked as one of “America's Best Children's Hospitals” in all 10 specialties rated by U.S. News & World Report and has received MagnetTM recognition for excellence in nursing services four consecutive times. With 366 licensed beds and a medical staff of more than 750 pediatric subspecialists, we care for children from all 50 states and from around the world. In addition, our leadership in pediatric genomic medicine and individualized pediatric therapeutics is driving research and innovation in neonatology, nephrology, endocrinology, gastroenterology, neurology, heart, cancer and other subspecialties to transform outcomes for children. Children’s Mercy is also nationally recognized for innovation in psychosocial care and creating a family-centered environment focused on the unique needs of hospitalized children and their families. Our love for children powers everything we do, inspiring our research, innovations and our everyday care. Because love has no limits. And with it, neither do we.